| Year |
Title |
Type |
| 2013 |
Efficacy and cost-effectiveness of new oral anticoagulants compared to warfarin for the prevention of stroke in patients with atrial fibrillation
|
Report from NOKC
|
| 2012 |
Pemetrexed as maintenance therapy for advanced, non-squamous, non-small cell lung cancer (NSCLC)
|
Report from NOKC
|
| 2012 |
Treatment of erythema migrans with antibiotics
|
Memorandum
|
| 2012 |
Early ultrasound in routine pregnancy care
|
Memorandum
|
| 2011 |
Cancer risk with folic acid supplements
|
Report from NOKC
|
| 2011 |
Health economic evaluation of thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin in patients undergoing elective hip- or knee replacement surgery
|
|
| 2011 |
Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery
|
Report from NOKC
|
| 2011 |
Efficacy and cost-effectiveness of alendronate for the prevention of fractures in postmenopausal women in Norway
|
Report from NOKC
|
| 2011 |
A systematic review and economic evaluation of prasugrel compared to clopidogrel after PCI
|
Report from NOKC
|
| 2011 |
Biologics for early rheumatoid arthritis: Review of health economic studies
|
Report from NOKC
|
| 2010 |
Prevention of drug harm in the elderly
|
Memorandum
|
| 2010 |
Treatment and rehabilitation of stroke patients
|
Memorandum
|
| 2010 |
Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke
|
Report from NOKC
|
| 2010 |
Health economic evaluation of intravenous thrombolytic treatment
|
|
| 2010 |
Health economic evaluation of antiplatelet therapy in the secondary prevention of stroke
|
|
| 2010 |
Methylnaltrexone for Opioid-induced Constipation
|
|
| 2010 |
Cost-effectiveness of Drugs for Smoking Cessation in Norway
|
|
| 2010 |
Health economic evaluation of acute treatment of patients in stroke unit
|
|
| 2010 |
Relative efficacy, safety and cost-effectiveness of nicotine replacement therapy, bupropion and varenicline for smoking cessation in Norway
|
|
| 2010 |
Treatment of patients with acute stroke in stroke units (with or without early supported discharge)
|
Report from NOKC
|
| 2010 |
Treatments to reduce the need for surgical intervention in people with osteoarthritis
|
Memorandum
|
| 2010 |
Effects of psychomotorical therapy and treatment in a hot climate on sickness absence and employability in people with fibromyalgia
|
Memorandum
|
| 2010 |
Cost-effectiveness of varenicline, bupropion and nicotine replacement therapy for smoking cessation
|
Report from NOKC
|
| 2010 |
Biologics for early rheumatoid arhritis
|
Report from NOKC
|
| 2010 |
Drugs for smoking cessation
|
Report from NOKC
|
| 2010 |
Antibiotic therapy in hospital, oral versus intravenous treatment
|
Report from NOKC
|
| 2009 |
Cost-effectiveness of childhood vaccination against rotavirus in Norway
|
Report from NOKC
|
| 2009 |
Methylnaltrexone for Opioid-induced Constipation in Cancer Treatment
|
Report from NOKC
|
| 2009 |
Prophylactic treatment for cluster headache
|
Memorandum
|
| 2009 |
Efficacy and safety of first-generation and second- generation anti psychotic drugs for schizophrenia in adults. An overview of systematic reviews
|
Report from NOKC
|
| 2009 |
Health economic analysis of bevacizumab+paclitaxel versus paclitaxel alone as first-line treatment for metastatic breast cancer
|
Report from NOKC
|
| 2009 |
Misoprostol for induction of labour
|
Report from NOKC
|
| 2008 |
TNFα-inhibitors in inflammatory bowel disease
|
Report from NOKC
|
| 2008 |
Efficacy and safety of angiotensin receptor blockers alone and in combination with diuretics in patients with hypertension, heart failure or diabetic nephropathy
|
Report from NOKC
|
| 2008 |
Estimating uncertainties of HPV16/18 vaccination – a dynamic modelling approach
|
Report from NOKC
|
| 2008 |
Immunomodulatory treatments with intravenous immunoglobulin
|
Report from NOKC
|
| 2008 |
Comparison of palonosetron with ondansetron, with respect to clinical efficacy and cost effectiveness in the prevention of chemotherapy induced nausea and vomiting in cancer patients
|
Report from NOKC
|
| 2008 |
Summary of published health economic studies of cetuximab as third line treatment for patients with metastatic colorectal cancer
|
Report from NOKC
|
| 2007 |
Health economic evaluation of bevacizumab for metastatic colorectal cancer
|
Report from NOKC
|
| 2007 |
Efficacy and safety for the newer antidepressants in adults
|
Report from NOKC
|
| 2007 |
TNF-α inhibitors and efalizumab for the treatment of skin diseases
|
Report from NOKC
|
| 2007 |
Prophylactic vaccines against human papillomavirus
|
Report from NOKC
|
| 2007 |
Efficacy and safety of 5HT1B/D reseptoragonists, triptans, for the treatment of migraine disorders
|
Report from NOKC
|
| 2007 |
Tumor necrosis factor (TNF) inhibitors for rheumatic diseases (part 2): a systematic review of data from registries and safety databases
|
Report from NOKC
|
